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abstract
PURPOSE The use of standardized structured reporting (SSR) can improve communication between cancer
specialists, which might improve clinical care; however, there are no reliable data on whether the introduction of
SSR is associated with improvements in clinical outcome.
PATIENTS AND METHODS We performed a retrospective cohort study in the Netherlands, including all patients
with colorectal cancer (CRC) from 2009 to 2014. As a reference, cohorts of 2007 and 2008 were included. Data
from the Netherlands Cancer Registry were used and combined with data from the Dutch Pathology Registry
(PALGA) and the Dutch ColoRectal Audit. We tested the preformulated hypothesis that use of SSR improves the
care of patients with CRC by improving the completeness of the pathology reports, the quality of the pathology
evaluation, and patient outcomes with respect to treatment and survival.
RESULTSWe included 72,859 patients with CRC (23.8% reference, 32.9% SSR, and 43.3% narrative reports).
Use of SSR increased over time, which resulted in more complete pathology reports (95.8% v 89.8%; P, .001).
Risk assessment in stage II colon cancer was more adequate and resulted in an increased delivery of adjuvant
therapy in patients with SSR (19.6% v 15.1%; P = .001). Risk of death for patients in the SSR group was
signiﬁcantly lowered (corrected hazard ratio, 0.94; 95% CI 0.90 to 0.97).
CONCLUSION We demonstrate that use of SSR improved patient care in those with CRC by providing more
complete reports of higher quality, which had signiﬁcant effects on the delivery of adjuvant therapy and patient
outcomes.
Clin Cancer Inform. © 2019 by American Society of Clinical Oncology
INTRODUCTION
With the increasing complexity of modern multidis-
ciplinary cancer treatment, adequate exchange of
diagnostic information is increasingly important. Post-
operative pathology reports describe the deﬁnitive
staging and typing of tumors and are the basis of ad-
ditional treatment plans. For colorectal cancer (CRC),
the decision of whether to administer adjuvant che-
motherapy is dependent on tumor stage and high-risk
features. It has been demonstrated that adjuvant
chemotherapy results in a survival beneﬁt for all stage III
patients and those with high-risk stage II disease.1 High-
risk features of stage II CRC—poor differentiation, ex-
tramural vascular invasion (EMVI), tumor perforation,
T4, fewer than 10 examined lymph nodes, and ob-
struction/ileus—are mainly determined by the pathol-
ogist. Therefore, the accuracy and completeness of
pathology reports are important for adequate adjuvant
chemotherapy delivery and patient outcome.2
Traditional narrative reports (NRs) are no longer
considered adequate as it can be difﬁcult to distill the
necessary information from long-winded sentences
that describe morphologic features rather than clini-
cally relevant information. In standardized structured
reporting (SSR) systems, mandatory parameters are
deﬁned and presented in a standardized structure,
thereby improving informational content3. Use of these
systems has been shown to improve both the read-
ability and completeness of postoperative pathology
reports.4 Several smaller studies have proven that use
of SSR resulted in increased completeness for a variety
of prognostic factors, such as involvement of the cir-
cumferential resection margin (CRM),5-11 EMVI,5,9,11,12
and TNM stage.7,10,11,13 However, whether this also
leads to increased quality of the diagnostic process
and subsequent treatment decisions has not yet been
explored.
In the Netherlands, we introduced SSR nationwide for
CRC resections in 2009. All mandatory parameters
were deﬁned in the Dutch guidelines for the diagnosis
and treatment of CRC.14 To explore the impact of SSR
on the diagnosis and treatment of patients with CRC
and to test the hypothesis that the introduction of SSR
ASSOCIATED
CONTENT
Appendix
Author affiliations
and support
information (if
applicable) appear at
the end of this
article.
Accepted on February
4, 2019 and
published at
ascopubs.org/journal/
cci on May 9, 2019:
DOI https://doi.org/10.
1200/CCI.18.00104
1
Downloaded from ascopubs.org by ASCO, Ethan Feinstein on May 14, 2019 from 066.102.234.242
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
was associated with increased completeness of reporting,
increased reporting of quality indicators, and improved
patient outcomes, we performed a population-based ret-
rospective cohort study.
PATIENTS AND METHODS
Design, Data Sources, and Population
We conducted a population-based retrospective nation-
wide cohort study in which all surgically treated patients
with primary CRC diagnosed between 2007 and 2014 from
the Netherlands Cancer Registry (NCR) were included.15
Data from the NCR were used as all data were retrieved
from both the NR and SSR for this registration. NR and SSR
were compared for all outcome measures from the in-
troduction of SSR in 2009 until 2014. To observe ongoing
trends independent of the introduction of SSR, we used
cohorts from 2007 to 2008 as a reference group. Linkage of
the NCR with the Dutch Pathology Registry—PALGA16
—and the Dutch ColoRectal Audit (DCRA; formerly the
Dutch Surgical Colorectal Audit)17 was performed. PALGA
is the nationwide network and registry of histo- and cyto-
pathology in the Netherlands, with nationwide coverage
since 1991. The DCRA is part of the Dutch Institute for
Clinical Auditing and registers all patients who undergo
surgery for CRC since 2009.
Patients were selected using International Classiﬁcation of
Diseases, Oncology codes (3rd edition18) C18.0 to C18.9
(colon, excluding appendix C18.1), C19.9 (rectosigmoid),
and C20.9 (rectum). Rectosigmoid tumors were classiﬁed
as either colon or rectum on the basis of the conclusions of
the pathology reports. Patients with CRC who did not un-
dergo resection, patients with multiple synchronous CRC or
in situ carcinomas, and resection specimens without tumor
were excluded, as well as those CRC cases that were re-
ported with SSR before 2009 (minor pilot project, including
243 patients).
Variables retrieved from the NCR were as follows: gender,
age at diagnosis, follow-up time, vital status, year of di-
agnosis, localization, histologic type, histologic grade, inva-
sion depth (pT), nodal status (pN), presence of metastases
(pM), number of investigated and positive lymph nodes
(LNs), CRM, and primary treatment of CRC. Three high-risk
features, including EMVI data, obstruction, and bowel
perforation were retrieved from the DCRA. Type of report
(SSR or NR), date of resection, type of pathology laboratory
(academic/university associated v nonacademic/nonuniversity
associated), and random laboratory number were retrieved
from PALGA.
The Dutch SSR is considered level six on the Ontario Scale.3
Completeness, Quality Indicators, and Patient Outcomes
We assessed the completeness of pathology reports using
two different deﬁnitions: ﬁrst, overall completeness—that
is, the proportion of pathology reports that contained
all mandatory pathology parameters—and second,
parameter-speciﬁc completeness—that is, the proportion
of pathology reports in which an individual parameter was
reported. Parameters were selected according to the Dutch
guideline14 in combination with availability in the NCR and
DSCA. Six mandatory parameters—histologic type, histo-
logic grade, pT, pN, LN count, and CRM—and one optional
parameter—EMVI—were analyzed. Histologic grade was
analyzed for patients who did not receive neoadjuvant
therapy, and CRM was analyzed for patients with rectal
resections only. As the NCR began registrations of CRM in
2008, we could not perform this analysis in the 2007 cohort
reference group. EMVI was analyzed for patients who were
diagnosed in 2009 to 2014, because the registration of this
parameter by DCRA began in 2009. The other four pa-
rameters were analyzed for the whole study population.
The quality of pathology evaluation was deﬁned as the
proportion of pathology reports in which the informational
content corresponded to Dutch and international quality
standards. We examined the number of LNs,14 reporting of
EMVI,19 and CRM. In addition, we used the prognostic
power of these histologic factors as a surrogate marker for
quality.
To evaluate the effects of SSR on patient care, we analyzed
the proportion of patients with high-risk stage II colon
cancer who received adjuvant chemotherapy. In addition,
CONTEXT
Key Objective
To investigate the impact of standardized synoptic pathology reporting on the diagnosis and treatment of patients with
colorectal cancer in a nationwide cohort study.
Knowledge Generated
Implementation of standardized structured reporting of pathology ﬁndings for patients with colorectal cancer resulted in
increased completeness of pathology reports and higher-quality pathology evaluation, and was associated with better
outcome for patients.
Relevance
These ﬁndings support the widespread introduction of standardized structured pathology reporting in oncology.
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we analyzed the effect of SSR on patient survival. Survival
time was deﬁned as the time from diagnosis until death or
last follow-up date (January 31, 2016).
Statistical Analysis
Statistical analyses were performed using SAS Enterprise
Guide 7 (SAS/STAT User’s Guide; SAS Institute, Cary, NC),
and all statistical tests were two sided. We used basic
descriptive statistics to describe patient and tumor char-
acteristics for NR, SSR, and the reference group. Annual
and overall proportions were calculated for overall com-
pleteness, completeness of speciﬁc parameters, and
quality indicators for NR, SSR, the reference group, and the
total study population. We used univariable and multivar-
iable logistic regression analyses to describe the association
between the type of reporting and outcomemeasures using
crude and adjusted odds ratios (OR) with corresponding
95% CIs. Year of diagnosis was selected as an a priori
confounding factor and included in every model.
To investigate the impact of the implementation of SSR, we
plotted relevant outcome parameters against the consec-
utive case numbers before and after the introduction of
SSR. To allow for the interpretation of whether results were
based on casemix, we also plotted predicted values that
were based on the casemix parameters stated above. Per
hospital, cases before the introduction of SSR received
negative consecutive case numbers and case 0 represents
the ﬁrst case in which an SSR was used. Data from all
hospitals were pooled and we performed exponentially
weighted–moving average analysis to analyze changing
trends in outcome parameters that could be explained by
the implementation of SSR.20
Proportions of patients with high-, low-, and undetermined-
risk stage II colon cancer and the corresponding pro-
portions of patients who received adjuvant chemotherapy
were calculated for SSR and NR and analyzed using χ2
analyses and adjusted ORs. We used Kaplan-Meier curves
and log-rank tests to evaluate overall survival, stratiﬁed by
the type of reporting. Survival was also calculated for the
following quality indicators: EMVI (detected, not detected,
or missing), CRM (negative, positive, or missing), and
number of LNs (more or less than 10 or missing). The
prognostic value of quality indicators in NR and SSR was
assessed using the Akaike information content (AIC).21 Cox
proportional hazards analyses were used to obtain hazard
ratios (HR) and corresponding 95% CIs. Associations were
adjusted in multivariable analyses for age at diagnosis,
gender, year of diagnosis, localization of tumor (not for CRM
analysis), histologic type, histologic grade, TNM stage, and
type of pathology laboratory. We tested the proportional
hazards assumption using Schoenﬁeld residuals and found
it to be satisﬁed.
RESULTS
The initial selection from the NCR resulted in 109,560
primary CRCs from 105,720 patients who were diagnosed
between 2007 and 2014 (Fig 1). After linkage with PALGA
(n = 104,925; 95.8%) and exclusion of tumors of origin
other than colon or rectum (n = 16), in situ tumors (n =
4,044), CRC without surgical intervention (n = 20,676),
pT0 and pTx resections (n = 2,228), synchronous CRC (n =
3,913), and SSR from 2007 or 2008 (n = 243), a total of
73,805 CRCs that occurred in 72,859 patients were in-
cluded for analysis. Table 1 lists patient and tumor char-
acteristics of the study population. There were 17,489
pathology reports in the reference group (23.7%), 32,065
NR (43.4%), and 24,251 SSR (32.9%). Over time, use of
SSR increased from 11.1% in 2009 to 78.3% in 2014
(Fig 2A). In the teaching setting of academic pathology
laboratories, pathologists used NR more frequent than
SSR, as was the case in stage IV CRC, rectal cancer, and
those patients who were treated with neoadjuvant therapy.
SSR was used more frequently than NR for low-grade tu-
mors as well as for more adenocarcinomas, not otherwise
speciﬁed.
Completeness
In the reference group, 90.5% of reports were already
complete. As a result of the introduction of SSR, com-
pleteness increased (Fig 3A), whereas NR remained on the
level of the reference group (95.8% v 89.8%; OR, 2.6; 95%
NR
(n = 32,065)
Reference
(n = 17,489)
SSR
(n = 24,251)
Matched to DCRA
(n = 48,378)
NCR CRC
(N = 109,560)
Final data set
(n = 73,805)
No match with PALGA
Not invasive
pT0/pTx resection
SSR pilot phase
No resection
Synchronous tumors
No CRC
(n = 4,044)
(n = 2,228)
(n = 243)
(n = 4,635)
(n = 20,676)
(n = 3,913)
(n = 16)
FIG 1. Flowchart of the patients with colorectal cancers (CRCs) who
were included in the study. DCRA, Dutch ColoRectal Audit; NCR,
Netherlands Cancer Registry; NR, narrative report; PALGA, Dutch
Pathology Registry; SSR, standardized structured reporting.
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CI, 2.4 to 2.7). After correction for year of diagnosis, the
same effect remained (OR, 2.3; 95% CI, 2.2 to 2.5). For all
parameters, SSR demonstrated a higher or similar per-
centage of completeness compared with NR (Fig 2B and
Appendix Table A1). However, histologic type, invasion
depth, LN count, and nodal stage were already reported in
more than 99% of NR.
Quality Indicators
Introduction of SSR was associated with a remarkable
increase in the number of investigated LNs (Fig 3B). As
a consequence, there was a signiﬁcant increase in the
number of cases in which more than 10 LNs were
investigated (SSR, 89.3% vNR, 77.3%; OR, 1.8; 95% CI,
1.7 to 1.9, adjusted for year of diagnosis; Fig 2C). There
was a small difference in the detection of EMVI (SSR,
17.1% v NR, 16.1%; P = .003). Although the reporting of
the CRM increased over time (Fig 2D), there was no
difference in the percentage of CRM positivity. To de-
termine the adequacy of the histologic features reported,
we compared the prognostic value of those features in the
different settings applying AIC statistics. The prognostic
model was better in the SSR cases for EMVI (AIC, 92,966 v
169,371; Appendix Figs A1, A2), CRM involvement (AIC,
12,322 v 46,956; Appendix Figs A3, A4), and number of LNs
(AIC, 80,397 v 1,123,778; Appendix Figs A5, A6).
TABLE 1. Patient and Tumor Characteristics
Characteristic Total No. Reference NR SSR P* P†
Patients, No. 72,859 17,315 31,566 23,978 — —
Age, years, %
, 50 5.2 5.6 4.4 .002 , .001
50-69 41.8 43.3 41.5 — —
≥ 70 53.0 51.1 54.1 — —
Male sex, % 53.7 54.9 54.3 .01 .20
CRC, No. 73,805 17,489 32,065 24,251 — —
Localization, %
Colon 73.5 69.5 79.1 , .001 , .001
Rectum 26.5 30.5 20.9 — —
Type, %
Adenocarcinoma 84.3 85.6 88.6 .001 , .001
Other 15.7 14.4 11.4 — —
Grade, %
Low 81.9 83.7 88.2 .001 , .001
High 18.1 16.3 11.8 — —
Missing, No. 6733 14,579 7,674 — —
TNM, %
I 19.4 22.3 21.6 , .001 , .001
II 34.2 33.4 34.5 — —
III 31.4 30.8 32.7 — —
IV 15.0 13.5 11.2 — —
Missing, No. 1,699 838 142 — —
Neoadjuvant Tx, %
Yes 22.3 28.1 14.6 , .001 , .001
Adjuvant Tx, %
Yes 26.8 25.2 26.4 , .001 , .001
Pathology, %
Academic laboratory 8.5 12.0 5.7 , .001 , .001
NOTE. Missing data are excluded from P value calculations.
Abbreviations: CRC, colorectal cancer; NR, narrative report; SSR, standardized structured reporting; Tx, therapy.
*Comparison of NR v reference.
†SSR v NR.
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Impact on Patient Care and Outcome
The data set consisted of 12,366 patients with stage II colon
cancer who were diagnosed between 2009 and 2014 and
who were potentially eligible for adjuvant therapy. Of these,
7,202 patients were considered low risk (SSR, 64.2% vNR,
52.7%; P , .001) and 4,381 patients were high risk (SSR,
31.2% v NR, 39.4%; P , .001). Risk status could not be
determined for 783 patients as a result of missing in-
formation on one or more risk factors (SSR, 4.6% v NR,
8.0%; P , .001). Of high-risk patients with SSR, 19.6%
received chemotherapy compared with 15.1% of high-risk
patients with NR (P = .001), even when corrected for year
of diagnosis, gender, and age (adjusted OR, 1.29; 95% CI,
1.06 to 1.57). No difference in chemotherapy adminis-
tration was observed for low-risk patients, nor for patients
with an unknown risk status. Overall survival in the high-risk
group was signiﬁcantly better in patients with SSR (65.0% v
62.4%; P = .026; Fig 4A). No differences were observed for
patients with low or unknown risk in relation to the type of
report.
Crude 5-year overall survival for patients with an SSR was
higher compared with patients with an NR (64.9% v
62.2%; P , .001; Fig 4B). As there were signiﬁcant dif-
ferences in stage, grade, and neoadjuvant therapy between
SSR andNR (Table 1), we adjusted for these factors, as well
as for age at diagnosis, gender, year of diagnosis, locali-
zation of tumor, histologic type, and type of pathology
laboratory. The difference remained present after adjust-
ment (HR, 0.94; 95% CI, 0.90 to 0.97).
DISCUSSION
We demonstrated that the nationwide implementation of
SSR for CRC resection specimens resulted in improved
completeness and quality of pathology reports, and we
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have described the effects on patient care. Improved
completeness was expected on the basis of previous
studies4; however, these studies were relatively small, with
only one study that included more than 1,000 SSR.
Completeness for individual parameters was highly
variable, but well below the 60% as a starting point for
many parameters, such as resection margins6,12,22 and
stage.10,11,13 Our reference group presented with more
than 90% total completeness; therefore, we expected
a limited effect of SSR on completeness. This potentially
limited the impact of the introduction on health care
improvement; however, we demonstrated that SSR fur-
ther improves reporting of all relevant items to 95% to
100%, which is in line with other publications.9,10,23,24
The improvement is particularly pronounced for more re-
cently recognized parameters, such as EMVI and CRM.4
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Of more importance, we also proved that the introduction of
SSR leads to better-quality pathology reporting. Increased
awareness of the critical issues in pathology assessment,
such as CRM in rectal cancer and numbers of LNs in CRC,
began before the introduction of SSR in the Netherlands, as
can be observed in Figures 2C and 2D, with increased
reporting since 2007. The introduction of SSR accelerated
this process, as can be observed from the rapid increase in
the proportion of complete reports (Fig 3A) and the mean
number of examined LNs per laboratory after they started
with SSR (Fig 3B). To evaluate the improved quality of
pathologic examination, the use of predeﬁned quality in-
dicators, such as LN count, EMVI detection remains to
a certain extent artiﬁcial.
Numerous studies have examined the quality of micro-
scopic evaluation by comparing the results of slide sets
scored by different groups of pathologists25-28; however,
clinical relevance is more directly investigated if the relation
of a prognostic factor with outcome is evaluated. Therefore,
we examined the prognostic value of the different histologic
factors in both the SSR and NR settings and compared their
AIC values, as is often used in comparing different staging
systems.29 We were able to show that for all relevant factors
the prognostic value was better when SSR was used. This
suggests that increased awareness, perhaps in combina-
tion with the possibility of directly checking the deﬁni-
tions (provided in SSR setting), leads to better histologic
evaluation.
The effect of improved communication on patient care has
been evaluated in the setting of multidisciplinary team
meetings.30 In general, these studies report higher rates of
appropriate treatment, better adherence to clinical guide-
lines, and better survival.31-33 In the current study, we have
focused on these items as a measurement of the effects on
patient care. We demonstrated that the administration of
adjuvant chemotherapy in patients with high-risk stage
II disease was signiﬁcantly higher in those with SSR. In
addition, appropriate staging occurred in more patients,
particularly with regard to discriminating patients with
high-risk from low-risk stage II CRC. Use of SSR in-
directly leads to outcome beneﬁts, as demonstrated by
the difference in overall survival between patients with
SSR and NR, which remains present after adjustment
for the year of diagnosis and patient and tumor char-
acteristics. We realize that in the current setup, inherent
biases are present that might reﬂect the higher quality of
the multidisciplinary team rather than use of SSR.
However, given the results from the ﬁgures that show
changing trends before and after the introduction
of SSR (Fig 3), this bias does not explain the whole
effect.
Nevertheless, a randomized clinical trial is the most ap-
propriate design to test the effects on patient outcomes;
however, such a design is impractical under the current
circumstances because of the widespread implementation
of SSR in our country. Therefore, we adopted a whole
population cohort study in which we controlled for po-
tentially confounding factors, such as the type of hospital
and the year of diagnosis. We therefore believe that our
ﬁndings are robust.
In conclusion, the nationwide implementation of
SSR for CRC resulted in increased completeness
of pathology reports, higher-quality pathology evaluation,
and better outcomes for patients. These ﬁndings
support the widespread introduction of SSR in
oncology.
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APPENDIX
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FIG A1. Survival curves to study the impact of positive, negative, and unknown extramural vascular invasion for
standardized structured reporting.
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FIG A2. Survival curves to study the impact of positive, negative, and unknown extramural vascular invasion for
standardized structured reporting and narrative report.
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FIG A4. Survival curves for the impact of circumferential resection margin involvement for rectal carcinoma for
narrative report.
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FIG A3. Survival curves for the impact of circumferential resection margin involvement for rectal carcinoma for
standardized structured reporting.
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FIG A5. Survival curves for the impact of 10 or more examined lymph nodes for standardized structured reporting.
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FIG A6. Survival curves for the impact of 10 or more examined lymph nodes for narrative report.
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TABLE A1. Effects of SSR on Completeness and Quality Indicators
Variable Reference, % NR, % SSR, %
Crude OR
(95% CI)
Adjusted OR
(95% CI)
P
Reference v NR
P
NR v SSR
Overall completeness 90.6 89.8 95.8 2.58 (2.40 to 2.78) 2.33 (2.15 to 2.52) .006 , .001
Parameter-speciﬁc completeness
Histologic type 100 100 100 NA NA NA NA
Histologic grade 96.9 92.1 95.8 1.96 (1.80 to 2.14) 1.97 (1.79 to 2.18) , .001 , .001
Invasion depth 100 99.9 100 NA NA .20 .07
Nodal status 98.4 99.0 99.7 3.38 (2.61 to 4.39) 2.98 (2.24 to 3.96) , .001 , .001
Lymph node count 98.8 99.5 99.9 6.24 (3.83 to 10.2) 4.56 (2.69 to 7.73) , .001 , .001
EMVI — 88.9 96.9 3.86 (3.55 to 2.41) 2.17 (1.98 to 2.38) NA , .001
CRM 75.5 84.9 96.1 4.34 (3.73 to 5.06) 3.63 (3.06 to 4.30) , .001 , .001
Quality indicators
At least 10 lymph nodes investigated 63.3 77.3 89.3 2.46 (2.34 to 2.58) 1.77 (1.68 to 1.87) , .001 , .001
Presence of EMVI — 16.1 17.1 1.08 (1.03 to 1.13) 1.08 (1.02 to 1.14) NA .003
Negative CRM 88.5 94.3 95.5 1.27 (1.08 to 1.50) 1.13 (0.94 to 1.37) , .001 .004
NOTE. Adjusted OR is corrected for year of diagnosis.
Abbreviations: CRM, circumferential margin; EMVI, extramural vascular invasion; NA, not assessable; NR, narrative reporting; OR, odds ratio; SSR,
standardized structured reporting.
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